Nothing Special   »   [go: up one dir, main page]

SI2609916T1 - Novi terapevtski pristopi za zdravljenje CMT in s tem povezanih motenj - Google Patents

Novi terapevtski pristopi za zdravljenje CMT in s tem povezanih motenj

Info

Publication number
SI2609916T1
SI2609916T1 SI200832028T SI200832028T SI2609916T1 SI 2609916 T1 SI2609916 T1 SI 2609916T1 SI 200832028 T SI200832028 T SI 200832028T SI 200832028 T SI200832028 T SI 200832028T SI 2609916 T1 SI2609916 T1 SI 2609916T1
Authority
SI
Slovenia
Prior art keywords
related disorders
new therapeutic
therapeutic approaches
treating cmt
cmt
Prior art date
Application number
SI200832028T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Oxana Guerassimenko
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of SI2609916T1 publication Critical patent/SI2609916T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI200832028T 2007-11-30 2008-11-28 Novi terapevtski pristopi za zdravljenje CMT in s tem povezanih motenj SI2609916T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03
EP12196650.1A EP2609916B1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating CMT and related disorders

Publications (1)

Publication Number Publication Date
SI2609916T1 true SI2609916T1 (sl) 2019-03-29

Family

ID=39264515

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200832028T SI2609916T1 (sl) 2007-11-30 2008-11-28 Novi terapevtski pristopi za zdravljenje CMT in s tem povezanih motenj
SI200830954T SI2211846T1 (sl) 2007-11-30 2008-11-28 Nov terapevtski pristop za zdravljenje cmt in z njo povezanih nepravilnosti

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200830954T SI2211846T1 (sl) 2007-11-30 2008-11-28 Nov terapevtski pristop za zdravljenje cmt in z njo povezanih nepravilnosti

Country Status (24)

Country Link
US (6) US8992891B2 (sl)
EP (4) EP2065038A1 (sl)
JP (4) JP5953000B2 (sl)
KR (1) KR101546031B1 (sl)
CN (2) CN101883561B (sl)
AU (1) AU2008328745B2 (sl)
BR (1) BRPI0819678A2 (sl)
CA (3) CA2705408C (sl)
CY (2) CY1113980T1 (sl)
DK (2) DK2609916T3 (sl)
EA (3) EA019402B1 (sl)
ES (3) ES2703508T3 (sl)
HR (2) HRP20130345T1 (sl)
HU (1) HUE040596T2 (sl)
IL (1) IL205741A0 (sl)
LT (1) LT2609916T (sl)
MX (1) MX2010005709A (sl)
NZ (1) NZ585440A (sl)
PL (2) PL2211846T3 (sl)
PT (2) PT2211846E (sl)
SI (2) SI2609916T1 (sl)
TR (1) TR201819564T4 (sl)
WO (1) WO2009068668A1 (sl)
ZA (1) ZA201003610B (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9494605B2 (en) * 2009-11-20 2016-11-15 Pharnext Diagnostic tools for charcot-marie-tooth disease
RS56080B1 (sr) * 2010-01-15 2017-10-31 Inserm (Institut Nat De La Santé Et De La Rech Médicale) Inhibitori nkcc za lečenje autizma
AU2011311531B2 (en) * 2010-10-08 2014-11-20 Life Sciences Research Partners Vzw HDAC inhibitors to treat Charcot-Marie-Tooth disease
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
JP2014511382A (ja) 2011-02-23 2014-05-15 コエルルウス リミテッド フルマゼニル錯体、それを含む組成物、およびその使用
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
WO2014063163A1 (en) 2012-10-19 2014-04-24 Block Jonathan D Systems and methods for nerve mapping and monitoring
EP2931267A1 (en) * 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
CN105473131A (zh) 2013-06-05 2016-04-06 法奈克斯公司 用于组合的活性药物成分的稳定口服溶液
US10905672B2 (en) 2014-02-11 2021-02-02 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
BR112016019395A2 (pt) * 2014-02-24 2017-10-24 Pharnext composição
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
US11136577B2 (en) 2016-03-09 2021-10-05 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
WO2018014007A1 (en) * 2016-07-14 2018-01-18 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
WO2018076060A1 (en) 2016-10-26 2018-05-03 Genea Ip Holdings Pty Ltd Improved generation of muscle lineage cells and therapeutic uses thereof
MX2020001057A (es) 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
BR112021021939A2 (pt) 2019-05-07 2022-02-22 Ucl Business Ltd Tratamento e detecção de neuropatias herdadas e distúrbios associados
JP2023524504A (ja) * 2020-05-01 2023-06-12 アプライド セラピューティクス， インコーポレイテッド ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
KR20010030798A (ko) 1997-09-30 2001-04-16 스즈키 다다시 경구 투여 제제
EP1115864A2 (en) * 1998-09-22 2001-07-18 Incyte Genomics, Inc. Human chaperone proteins
JP2002526417A (ja) * 1998-10-02 2002-08-20 セルトリックス ファーマシューティカルズ，インコーポレイテッド 非甲状腺性疾患の治療方法
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
WO2003011255A1 (en) * 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
CA2478558C (en) * 2002-03-14 2012-09-11 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
SI1578350T1 (sl) * 2002-03-26 2009-10-31 Euro Celtique Sa Z gelom obloženi sestavki z zadržanim sproščanjem
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
KR101170844B1 (ko) * 2003-02-24 2012-08-02 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
WO2004091623A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
US20060194826A1 (en) * 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
ATE511392T1 (de) 2007-01-11 2011-06-15 Xenoport Inc Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
PT2560631E (pt) 2011-03-01 2014-02-24 Pharnext Terapia à base de baclofeno e acamprosato de distúrbios neurológicos
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
CN105473131A (zh) 2013-06-05 2016-04-06 法奈克斯公司 用于组合的活性药物成分的稳定口服溶液
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
CN104257657B (zh) 2017-07-04
CY1113980T1 (el) 2016-07-27
TR201819564T4 (tr) 2019-01-21
MX2010005709A (es) 2010-11-05
EP2211846B1 (en) 2013-02-27
US20180360785A1 (en) 2018-12-20
NZ585440A (en) 2011-12-22
EP2609916B1 (en) 2018-11-07
DK2211846T3 (da) 2013-04-29
PT2609916T (pt) 2019-01-10
EA201791669A2 (ru) 2017-12-29
CA3031490A1 (en) 2009-06-04
EP3459535A1 (en) 2019-03-27
US10463640B2 (en) 2019-11-05
US20180250289A1 (en) 2018-09-06
ES2831855T3 (es) 2021-06-09
HRP20182147T8 (hr) 2019-04-19
WO2009068668A1 (en) 2009-06-04
HUE040596T2 (hu) 2019-03-28
ZA201003610B (en) 2011-06-29
CA2705408A1 (en) 2009-06-04
PL2609916T3 (pl) 2019-03-29
JP2011504915A (ja) 2011-02-17
US20200155491A1 (en) 2020-05-21
EP2609916A1 (en) 2013-07-03
EP3459535B1 (en) 2020-08-12
CY1121183T1 (el) 2020-05-29
EA032767B1 (ru) 2019-07-31
JP2019142917A (ja) 2019-08-29
SI2211846T1 (sl) 2013-07-31
ES2703508T3 (es) 2019-03-11
EA201301078A1 (ru) 2014-06-30
EA019402B1 (ru) 2014-03-31
US8992891B2 (en) 2015-03-31
US20150157626A1 (en) 2015-06-11
HRP20130345T1 (hr) 2013-07-31
CN101883561B (zh) 2014-07-30
EA201000914A1 (ru) 2010-12-30
CN104257657A (zh) 2015-01-07
US10441558B2 (en) 2019-10-15
JP5953000B2 (ja) 2016-07-13
JP2016145227A (ja) 2016-08-12
EP2211846A1 (en) 2010-08-04
AU2008328745B2 (en) 2014-01-30
US10322101B2 (en) 2019-06-18
BRPI0819678A2 (pt) 2017-05-09
CA3031484A1 (en) 2009-06-04
CA2705408C (en) 2019-04-23
EA035711B1 (ru) 2020-07-29
CA3031484C (en) 2021-05-04
KR101546031B1 (ko) 2015-08-25
LT2609916T (lt) 2019-02-11
CN101883561A (zh) 2010-11-10
CA3031490C (en) 2021-05-04
US20100310641A1 (en) 2010-12-09
PL2211846T3 (pl) 2013-09-30
PT2211846E (pt) 2013-05-10
JP6608309B2 (ja) 2019-11-20
ES2408785T3 (es) 2013-06-21
EP2065038A1 (en) 2009-06-03
IL205741A0 (en) 2010-11-30
DK2609916T3 (en) 2019-01-21
JP2018109043A (ja) 2018-07-12
EA201791669A3 (ru) 2018-03-30
HRP20182147T1 (hr) 2019-03-08
US20180338969A1 (en) 2018-11-29
KR20100088160A (ko) 2010-08-06
AU2008328745A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
HRP20182147T1 (hr) Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja
HK1259102A1 (zh) 用於治療微生物病症的amp
IL197001A0 (en) Combination treatment for metabolic disorders
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
GB0602178D0 (en) Therapeutic treatment
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
IL205730A0 (en) Methods for treating obesity and obesity related diseases and disorders
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
HK1170150A1 (en) New compositions for treating cmt and related disorders
IL222557A (en) A compound for use in treating mutant disorders has ruled
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
IL201422A0 (en) Therapeutic agents useful for treating pain
GB0608655D0 (en) Therapeutic Treatment
ZA201002167B (en) Treatment regime for proliferative disorders
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
GB0610909D0 (en) Therapeutic treatment
PT2481407T (pt) Compostos para utilização no tratamento de distúrbios cognitivos
GB0702537D0 (en) Treatment for excessive adiposity
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL207906A0 (en) Treatment for ocular-related disorders
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
GB0610376D0 (en) Therapeutic treatment
HK1145282A1 (en) Treatment of sleep disorders